ROS1 Treatment Options: Crizotinib and Entrectinib – 2022 Program: Targeted Therapies Forum

Unravel the complexities of ROS1+ NSCLC treatment with Dr. Alejandro Calvo. In this illuminating segment from the 2022 Targeted Therapies Forum, delve into the details of Crizotinib and Entrectinib — two promising medications championed for ROS1+ NSCLC care.

We’d like to express our heartfelt gratitude to our incredible sponsors for their continued support: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech.

Eager to delve deeper into the realm of innovative cancer treatments? Discover more at http://cancerGRACE.org/. Engage with our dynamic community and leading experts at https://cancergrace.org/forum.